AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02472873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Study NCT02654314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5 mg Melatonin nightly, beginning within 24 hours of admission
Study NCT01991873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance Chemotherapy
Study NCT01991873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab (Within maintenance phase)
Study NCT02654314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blue capsule matching the melatonin arm
Study NCT01991873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (Within re-induction phase)
Study NCT04004546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health literacy-based intervention
Description: Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
Study NCT00594048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resperate
Description: Use of the device 15 minutes a day for 9 weeks
Study NCT00594048 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: discman with freely chosen music
Description: Use the discman 15 minutes a day for 9 weeks
Study NCT04478981 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This concerns a natural history study; no interventions will be used
Study NCT01991873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab (Within re-induction phase)
Study NCT01827189 — intervention group
Intervention type: OTHER
Intervention: Comprehensive primary care
Description: Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
Study NCT03427619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OK432
Description: OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
Study NCT01652157 — intervention group
Intervention type: BIOLOGICAL
Intervention: ULTRESA
Description: pancreatic enzyme replacement therapy
Study NCT01652157 — intervention group
Intervention type: BIOLOGICAL
Intervention: PANCREAZE
Description: pancreatic enzyme replacement therapy
Study NCT01652157 — intervention group
Intervention type: BIOLOGICAL
Intervention: CREON
Description: pancreatic enzyme replacement therapy
Study NCT01652157 — intervention group
Intervention type: BIOLOGICAL
Intervention: ZENPEP
Description: pancreatic enzyme replacement therapy
Study NCT01652157 — intervention group
Intervention type: BIOLOGICAL
Intervention: other non-sponsor pancreatic enzyme replacement therapy
Description: pancreatic enzyme replacement therapy
Study NCT01652157 — intervention group
Intervention type: BIOLOGICAL
Intervention: PERTZYE
Description: pancreatic enzyme replacement therapy
Study NCT01652157 — intervention group
Intervention type: OTHER
Intervention: No pancreatic enzyme replacement therapy
Description: Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
Study NCT01275378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Care Plus
Description: Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
Study NCT01275378 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Collaborative Care
Description: Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
Study NCT00709657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab, bevacizumab or pegaptanib
Description: measurements are performed one week before and after anti-VEGF intravitreal injection
Study NCT03347669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sudoscan®
Description: Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
Study NCT03347669 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sudoscan®
Description: Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
Study NCT06558097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XXB750
Description: Single SC dose of XXB750 (administered by single or multiple injections)
Study NCT00556114 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Optical Coherence Tomography
Study NCT01117779 — intervention group
Intervention type: DEVICE
Intervention: Cryoablation
Description: Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
Study NCT02020226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: 480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
Study NCT04087642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative Crede manoeuver
Description: In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
Study NCT04087642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative prolapse reduction cough stress test
Description: In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
Study NCT01549652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 8 mg oral tablet
Study NCT01549652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match Ondansetron
Study NCT01549652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved
Study NCT01549652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg/70 kg
Description: Naloxone 0.4 mg/70 kg intravenous
Study NCT01549652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone 0.8 mg/70 kg
Description: Naloxone 0.8 mg/70 kg intravenous
Study NCT00586339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Intramuscular injection, 3 doses
Study NCT01464606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: ≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
Study NCT01464606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: ≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
Study NCT01464606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: ≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
Study NCT01464606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: ≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
Study NCT01464606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: ≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
Study NCT00586339 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Control
Description: Intramuscular injection, 3 doses
Study NCT01972152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen(TM) 1 mg
Study NCT01972152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-Pen(TM) 1 mg
Study NCT04184050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4002
Description: IV infusion
Study NCT03729609 — intervention group
Intervention type: DRUG
Intervention: Brentuximab vedotin (Genetical Recombination)
Description: Brentuximab vedotin Intravenous Infusion
Study NCT04626518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
Study NCT06558097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single SC dose of matching placebo (administered by single or multiple injections)
Study NCT03413800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide-Dexamethasone-DLI
Description: Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
Study NCT04023487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient, Empowered, Active Living-Telehealth (REAL-T)
Description: REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
Study NCT04626518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: Administered via IV infusion at a dose of 800 mg Q3W
Study NCT04626518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Administered via oral tablet at a dose of 120 mg QD
Study NCT01809769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells low-dose group
Description: Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
Study NCT01809769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells mid-dose group
Description: Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
Study NCT01809769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells high-dose group
Description: Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
Study NCT01220687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNO
Description: Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
Study NCT01220687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
Study NCT01533987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice Plus
Description: Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
Study NCT01533987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Juice Plus
Description: Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
Study NCT00601731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197
Description: Blood test, 40-months and 60-months children
Study NCT00601731 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Blood test, 40-months and 60-months children
Study NCT03563001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide(160ug) and Formoterol(4.5ug) bid
Description: For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
Study NCT03578055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDD with UDCA
Description: Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
Study NCT03578055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
Study NCT04388631 — intervention group
Intervention type: OTHER
Intervention: Coronavirus Disease 2019
Description: male patients who have developed COVID-19
Study NCT01437189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
Study NCT02735460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Andago V2.0
Description: The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
Study NCT04626518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a dose of 20 mg QD
Study NCT04103346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air filtration with air purifier with hepa filter
Description: long-term (4 week) air filtration with the Holmes HAP8650B-NU-1 air purifier in the residence of low-income seniors impacted by roadway pollutants.
Study NCT04103346 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: air purifier running with air filter removed
Study NCT04169009 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Intradermal injection of Zostavax
Study NCT04169009 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Given to subjects in Arm 4 who've never had a herpes zoster vaccine
Study NCT04511494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peanut (bamba)
Description: OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
Study NCT04419519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy
Description: Venetoclax monotherapy
Study NCT04419519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax with anti CD20 monoclonal antibody
Description: Venetoclax with anti CD20 monoclonal antibody
Study NCT04626518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Administered via IV infusion at a dose of 400 mg/25 mg Q6W
Study NCT04626518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/Pembrolizumab
Description: Administered via IV infusion at a dose of 800 mg/200 mg Q3W
Study NCT03677427 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation in breast cancer
Study NCT02124161 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13-valent pneumococcal conjugate vaccine
Description: One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
Study NCT02124161 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal Inactivated Influenza Vaccine
Description: One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
Study NCT02124161 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
Study NCT04014946 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implantation
Description: implantation of the Lumax 540 single/dual chamber ICD or successor
Study NCT03872154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist-guided shared decision-making
Description: Physicians will receive a checklist and a decision aid for shared decision-making during code status discussion.~Ancillary project: Physicians will receive a checklist to communicate the futility.
Study NCT00778544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension
Study NCT03598608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion every 3 weeks (Q3W)
Study NCT01149694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PUR 0110 Rectal Enema or Placebo Enema
Description: 187.5 mg/60 g
Study NCT01149694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PUR 0110 Rectal Enema or Placebo Enema
Description: 375 mg/60 g
Study NCT01149694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PUR 0110 Rectal Enema or Placebo Enema
Description: 750 mg/60 g
Study NCT01149694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PUR 0110 Rectal Enema or Placebo Enema
Description: 1500 mg/60 g
Study NCT03058874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extra-vascular lung water measurements by ultrasound
Description: Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
Study NCT03058874 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard protocol of fluid management in hemodialysis
Description: The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
Study NCT05429411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silicone gel
Description: At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach >21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
Study NCT02992730 — intervention group
Intervention type: BEHAVIORAL
Intervention: No Intervention
Description: No Intervention
Study NCT03090165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: 400mg PO
Study NCT03090165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: 600mg PO
Study NCT03090165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150mg PO
Study NCT04474873 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: we administer 15 cc of 0.5% bupivacaine between the erector spine muscle and the transverse process. The distribution of bupivacain was observed on ultrasound.
Study NCT01277185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Calcium Diet
Description: The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.